Why Nancy Pelosi-Owned Tempus AI Stock Is Down After Q2 Earnings - Tempus AI (NASDAQ:TEM)
Tempus AI (NASDAQ:TEM) reported second-quarter financial results Thursday after market close. Here are the key highlights. • Tempus AI stock is facing resistance. Why are TEM shares declining? Tempus AI Q2 Earnings Tempus AI revenue was $382.5 million in the second quarter, up 22% year-over-year. The revenue total beat a Street consensus estimate of $379.7 million, according to data from Benzinga Pro. Revenue for the Diagnostics segment was $289.3 million, up 20% year-over-year.
How this was made
The 30-second read
Why it matters
The key trade signal is the mismatch between a Q2 beat and the market’s focus on the next two quarters, driven by the described deceleration in revenue growth and only a modest guidance increase.
Market read
Post-earnings, the stock is down after hours as investors weigh strong segment growth against modest guidance and potentially slower near-term revenue growth.
What to watch
The article notes new data and applications licenses of about $200M and that full-year guidance excludes Personalis acquisition impact, which could matter for forward expectations.
Background
Tempus AI released Q2 results after the close and discussed segment growth, licensing activity, and full-year guidance.
Ticker impact
Tempus AI reported Q2 revenue of $382.5M, raised full-year revenue guidance only slightly, and shares fell 2.4% after hours.
Near-term downside bias until investors gain confidence that raised guidance translates into sustained quarterly growth.
The article cites a beat on revenue and EPS, but attributes the decline to lower-than-recent-quarter revenue growth and guidance that is described as minimal versus the beat.
Market effects
Signals that investors may be scrutinizing AI/diagnostics growth rates and data licensing momentum versus headline beats.
None indicated.
None indicated.
Counterpoint
The guidance raise and strong Oncology volume growth (up 31% YoY) and Data Licensing & Modeling growth (up 36% YoY) could mean the market is overreacting to quarter-to-quarter noise.
Key entities
- companyTempus AI
NASDAQ-listed precision oncology and data licensing company that reported Q2 results and raised full-year revenue guidance.
- executiveEric Lefkofsky
CEO quoted saying AI investments are driving growth in Oncology Diagnostics and Data Licensing.
- companyPersonalis
Acquisition expected to close late 2026 or early 2027; guidance cited as excluding its impact.
- personNancy Pelosi
Rep. Nancy Pelosi is described as owning Tempus AI stock.
